UK group steps up Ebolavirus vaccine development in response to outbreak
In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) has reported that it is working urgently with the Clinical BioManufacturing Facility and the Serum Institute of India (SIIPL) to rapidly produce and scale doses of its ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.
At the same time, the OVG is working with global partners to accelerate the generation of supportive preclinical data for the clinical development and testing of the ChAdOx1 BDBV vaccine in outbreak scenarios.
The ChAdOx platform, a type of viral-vector vaccine, has previously demonstrated a vital role in the development of vaccines for emerging infectious diseases and responding to outbreak scenarios. This platform underpinned the Oxford/AstraZeneca Covid-19 vaccine, which was estimated to have saved more than six million lives in its first year of use globally.
Professor Teresa Lambe OBE, Calleva Head of Vaccine Immunology at the Oxford Vaccine Group and Pandemic Sciences Institute said: “My hope is that this outbreak can be brought under control quickly and that vaccines are ultimately not needed. Nevertheless, our team and partners will continue working to ensure that potential vaccine options are available if they are needed. The ability to move rapidly in situations like this has been built on many years of vaccine research and close collaboration with our global partners.”
A history of outbreak response
The Group has historically responded to a number of outbreaks. In response to the 2013-2016 West African Ebola outbreak, OVG and the Jenner Institute led a number of clinical trials testing vaccines against Ebolavirus, including an expedited Phase II clinical trial of an adenovirus/MVA Ebola vaccine regimen, contributing to its approval by the European Medicines Agency in 2020.
During outbreaks in Uganda, Equatorial Guinea and Tanzania between 2022 and 2025, vaccines designed and tested by Professor Teresa Lambe and her team based in OVG and the Pandemic Sciences Institute were selected by the World Health Organization for inclusion in ring vaccination trials, should they have been needed.
